Section Arrow
PDSB.NASDAQ
- PDS Biotechnology Corp
Quotes are at least 15-min delayed:2025/06/06 01:20 EDT
Last
 1.57
-0.08 (-4.85%)
Day High 
1.6599 
Prev. Close
1.65 
1-M High
1.765 
Volume 
396.66K 
Bid
1.56
Ask
1.61
Day Low
1.56 
Open
1.64 
1-M Low
1.16 
Market Cap 
75.42M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.49 
20-SMA 1.41 
50-SMA 1.26 
52-W High 4.42 
52-W Low 0.8505 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.94/-1.00
Enterprise Value
84.69M
Balance Sheet
Book Value Per Share
0.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0393-0.0068-14.75%-- 
CLRBCellectar Biosciences0.399201-0.062499-13.54%-- 
RXRXRecursion Pharmaceuticals4.56-0.35-7.13%-- 
GLYCGlycoMimetics0.1994-0.0106-5.05%-- 
SCNIScinai Immunotherapeutics Ltd.3.07+0.55+21.83%1.21PE
Quotes are at least 15-min delayed:2025/06/06 01:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.